Bio-Techne Corp
SWB:TE1
Bio-Techne Corp
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide.
The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide.
The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
Revenue: Revenue for Q2 was $295.9 million, flat year-over-year and in line with expectations. Adjusting for large cell therapy customer timing, organic growth was 4%.
Margins: Adjusted operating margin expanded 100 basis points year-over-year to 31.1%, driven by cost discipline and productivity gains.
Growth Drivers: Strength in large pharma and solid performance in Asia offset ongoing softness in biotech and U.S. academia. Excluding two Fast Track cell therapy customers, cell therapy grew nearly 30%.
Cell Therapy Headwind: Temporary slowdown in GMP reagent demand due to two major customers receiving FDA Fast Track designation; this is expected to moderate by fiscal 2027.
China & APAC Momentum: China grew mid-single digits for the third straight quarter; APAC ex-China nearly 20%.
Outlook: Q3 organic growth expected to be consistent with Q2, with underlying business set for mid-single-digit growth as headwinds ease. Full-year organic growth view remains low single digits.
Cash Flow & M&A: Operating cash flow was $82.4 million for the quarter. M&A remains a top capital deployment priority.
Strategic Milestones: 50th anniversary year, progress in key verticals (cell therapy, proteomics, spatial biology, diagnostics), and ongoing Wilson Wolf acquisition.
